Grace Therapeutics FY27 Q1 net loss widens to $15.79 million; operating loss widens to $15.92 million
GRCE•Quarterly loss widens
- Grace Therapeutics posted a net loss of USD 15.79 million, widening from USD 3.36 million in the year-ago quarter.
- Loss per share widened to USD 0.91 from USD 0.21, reflecting a USD 13.53 million impairment of intangible assets.
Expenses decline year over year
- Research and development expense fell 27.02% to USD 697,000, while general and administrative costs declined 20.98% to USD 1.69 million.
Cash position and regulatory update
- Cash and cash equivalents ended the quarter at USD 13.76 million, down from USD 16.98 million at March 31, 2026.
- FDA issued a Complete Response Letter for GTx-104; a dual-source manufacturing strategy is underway ahead of an NDA resubmission.
